Musculoskeletal events associated with the management of endocrine-responsive breast cancer
Musculoskeletal symptoms have been reported in patients treated with third generation aromatase inhibitors (AIs) and with blockers of hypothalamic–pituitary gonadal axis. AIs act by suppressing postmenopausal estrogen biosynthesis through inhibition of the enzyme aromatase, which is responsible for...
Main Authors: | Anas Al-Janadi, Borys Hrinczenko, Vijay Chaudhary, Shalini Chitneni, Sarah Ali, Jennifer Saultz, Nikolay V. Dimitrov |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2011-12-01
|
Series: | Oncology Reviews |
Subjects: | |
Online Access: | http://www.oncologyreviews.org/index.php/or/article/view/64 |
Similar Items
-
Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management
by: Tara Hyder, et al.
Published: (2021-07-01) -
Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review
by: Angeliki Andrikopoulou, et al.
Published: (2021-01-01) -
Aromatase Inhibitors—Induced Musculoskeletal Disorders: Current Knowledge on Clinical and Molecular Aspects
by: Sara Tenti, et al.
Published: (2020-08-01) -
Aromatase inhibitors and risk of cardiovascular events in breast cancer patients: a systematic review and meta-analysis
by: Yang He, et al.
Published: (2019-10-01) -
What influences aromatase inhibitor continuation intention among breast cancer survivors?
by: Young Kyung Seo, et al.
Published: (2021-03-01)